Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
131.02
+0.34 (+0.26%)
Streaming Delayed Price
Updated: 3:50 PM EDT, Jun 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corporation Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 23, 2025
From
Glaukos Corporation
Via
Business Wire
Forecasting The Future: 7 Analyst Projections For Glaukos
↗
April 16, 2025
Via
Benzinga
Glaukos Announces the Release of its 2024 Sustainability Report
April 16, 2025
From
Glaukos Corporation
Via
Business Wire
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
↗
February 24, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
↗
February 20, 2025
Via
Benzinga
Peering Into Glaukos's Recent Short Interest
↗
February 12, 2025
Via
Benzinga
How Is The Market Feeling About Glaukos?
↗
January 27, 2025
Via
Benzinga
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today
↗
January 23, 2025
Via
Benzinga
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
April 09, 2025
From
Glaukos Corporation
Via
Business Wire
Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years
↗
March 28, 2025
Via
Benzinga
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution
March 11, 2025
From
Glaukos Corporation
Via
Business Wire
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
↗
February 24, 2025
Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.
Via
Benzinga
What 11 Analyst Ratings Have To Say About Glaukos
↗
December 31, 2024
Via
Benzinga
(GKOS) - Analyzing Glaukos's Short Interest
↗
December 26, 2024
Via
Benzinga
How Is The Market Feeling About Glaukos?
↗
December 03, 2024
Via
Benzinga
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
February 24, 2025
From
Glaukos Corporation
Via
Business Wire
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?
↗
February 21, 2025
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.
Via
Benzinga
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition
↗
February 21, 2025
Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model.
Via
Benzinga
Wondering what's happening in today's after-hours session?
↗
February 20, 2025
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
February 20, 2025
From
Glaukos Corporation
Via
Business Wire
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
↗
February 19, 2025
Via
Benzinga
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
January 23, 2025
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
January 14, 2025
From
Glaukos Corporation
Via
Business Wire
Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market
↗
January 13, 2025
TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation.
Via
Benzinga
Topics
Fraud
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
↗
December 31, 2024
Via
Benzinga
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
December 23, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 17, 2024
From
Glaukos Corporation
Via
Business Wire
Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 7
↗
December 07, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 2-6, 2024.
Via
Talk Markets
Topics
Stocks / Equities
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
↗
December 06, 2024
Via
Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
↗
December 02, 2024
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
